L3VLUP
ProSign in

ONC · VRTX in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

ONCVRTX
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • ONC
  • VRTX
010203040202120222023202420252026
Holders and value by quarter
QuarterONCVRTX
Q3 20205 holders, $2.9bn31 holders, $21.9bn
Q4 20209 holders, $2.9bn30 holders, $18.4bn
Q1 20219 holders, $4.7bn31 holders, $15.4bn
Q2 20219 holders, $4.2bn30 holders, $12.7bn
Q3 20216 holders, $4.4bn35 holders, $10.1bn
Q4 20216 holders, $3.2bn28 holders, $12.4bn
Q1 20224 holders, $2.0bn23 holders, $16.1bn
Q2 20224 holders, $1.5bn25 holders, $18.1bn
Q3 20225 holders, $1.2bn22 holders, $18.4bn
Q4 20226 holders, $2.1bn28 holders, $18.4bn
Q1 20237 holders, $1.8bn26 holders, $21.4bn
Q2 20236 holders, $1.5bn27 holders, $24.7bn
Q3 20234 holders, $1.7bn33 holders, $24.3bn
Q4 20232 holders, $1.0bn32 holders, $28.6bn
Q1 20244 holders, $926m31 holders, $29.8bn
Q2 20247 holders, $949m29 holders, $33.4bn
Q3 20247 holders, $1.6bn27 holders, $33.5bn
Q4 20244 holders, $1.3bn26 holders, $28.5bn
Q1 202514 holders, $3.4bn21 holders, $35.4bn
Q2 20256 holders, $1.3bn21 holders, $32.3bn
Q3 20258 holders, $2.1bn22 holders, $25.9bn
Q4 20259 holders, $1.8bn26 holders, $31.8bn
Q1 20269 holders, $2.1bn25 holders, $31.8bn
Q2 202612 holders, $2.5bn26 holders, $34.6bn
ONC

Beone Medicines LTD

Holders
14
Reported value
$3.4bn
Buyers
12
Sellers
2

Breadth +10 among 95 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations
VRTX

Vertex Pharmaceuticals Inc

Holders
21
Reported value
$35.4bn
Buyers
10
Sellers
11

Breadth -1 among 95 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q1 2025

Among the 30 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only ONC (9)

Citadel Advisors LLC, Farallon Capital Management LLC, Man Group PLC, Point72 Asset Management LP, Schonfeld Strategic Advisors LLC, Two Sigma Advisers LP, Two Sigma Investments LP, Voloridge Investment Management LLC, Walleye Capital LLC

Only VRTX (16)

AllianceBernstein LP, AQR Capital Management LLC, ARK Investment Management LLC, Capital Research Global Investors, Capital World Investors, Element Capital Management LLC, Hudson Bay Capital Management LP, Invesco Ltd, Janus Henderson Group Ltd, MFS Investment Management, Millennium Management LLC, Neuberger Berman Group LLC, PDT Partners LLC, Renaissance Technologies LLC, Wellington Management Group LLP, Woodline Partners LP

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →